PharmAust invited to apply for grant funding

PharmAust Limited (ASX:$PAA), a clinical-stage biotechnology company, has been invited by FightMND to submit a full grant application to help fund its Phase 2/3 Clinical Study for the treatment of Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS). The grant, offering up to AUD $1,800,000 in support, is available per successful application, with a deadline set for the 24th of March 2024. PharmAust's planned Phase 2/3 study is a multicentre, randomised, placebo-controlled, adaptive clinical study evaluating the safety and efficacy of monepantel in patients with MND/ALS over 48 weeks.

PharmAust CEO's perspective on the grant invitation

Gaining access to undiluted funds to help offset the costs of drug development is a goal of every biotechnology company. FightMND has already been influential to date in the development of monepantel for MND/ALS by fully funding our initial Phase 1 study. Based on the potential shown to date for monepantel to provide patients with MND/ALS with a treatment benefit were are excited at our prospects of securing further funding from FightMND for our adaptive Phase 2/3 study.

PharmAust's Phase 2/3 study and future outlook

PharmAust Limited (ASX:PAA) has been invited by FightMND to apply for grant funding to support its planned Phase 2/3 study, which aims to evaluate the safety and efficacy of monepantel in patients with MND/ALS over 48 weeks. The company's CEO, Dr Michael Thurn, expressed enthusiasm about the potential to secure further funding from FightMND for the adaptive Phase 2/3 study. PharmAust's focus on repurposing monepantel for human neurodegenerative diseases and treating cancer in dogs reflects its commitment to addressing critical health challenges. With the completion of a Phase 1 study in patients with MND/ALS and anticipated Phase 2 study in H1 2024, PharmAust is poised to contribute significantly to the advancement of treatments for MND/ALS and other related conditions.